Physician profile
Jaime Giron
NPI 1346321197
$7,276.38
in general payments reported to CMS, 2019-2025
29 companies · $894 in 2025
The $894 reported for 2025 was more than what 89% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $462 · 2021: $658 · 2022: $1,264 · 2023: $2,161 · 2024: $1,333 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,387.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,205.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,121.42 | 2019-2025 | |
| Lilly USA, LLC | $751.64 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.88 | 2023-2025 | Jardiance |
| Abbott Laboratories | $451.50 | 2022-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $444.99 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $427.34 | 2022-2025 | |
| Amgen INC. | $395.39 | 2019-2023 | Repatha, Otezla |
| Mylan Specialty L.P. | $267.48 | 2020-2024 | Yupelri |
| Pfizer INC. | $251.37 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.08 | 2020-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $179.86 | 2022 | |
| Allergan, INC. | $168.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $142.01 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $139.55 | 2023 | Farxiga |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $109.83 | 2022-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $91.09 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $88.93 | 2020-2023 | |
| Xeris Pharmaceuticals, INC. | $54.48 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $51.92 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $44.58 | 2021 | |
| Sanofi Pasteur INC. | $43.33 | 2019-2021 | |
| Philips North America LLC | $42.91 | 2019-2024 | (8874) Incourage |
| Merck Sharp & Dohme LLC | $32.06 | 2019-2020 | |
| Exact Sciences Corporation | $21.43 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $18.85 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.97 | 2024 | Voquezna |
| Redhill Biopharma INC. | $14.92 | 2020 | |
| Axsome Therapeutics, INC. | $14.91 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Giron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.